Navigation Links
Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
Date:11/16/2010

BEDMINSTER, N.J., and MILTON, Canada, Nov. 16, 2010 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Tribute Pharmaceuticals, a privately-held Canadian specialty pharmaceutical company, announced today their exclusive license agreement for the commercialization of CAMBIA™ (diclofenac potassium for oral solution) in Canada.  CAMBIA™ is approved in the United States for the acute treatment of migraine with or without aura and was launched in the United States in June 2010.  

"Canada is an important pharmaceutical market and opportunity for CAMBIA," said James Fares, Chairman and CEO, of Nautilus Neurosciences. "The management team at Tribute Pharmaceuticals has a wealth of experience in developing, launching and successfully commercializing new products in Canada.  This partnership along with recent developments in the US has significantly enhanced our ability to market CAMBIA™ to the broader North American market and reach more people suffering from acute migraine headaches.  We look forward to completing the expansion of our efforts through the addition of a partner for the family practice market in the United States in 2011."

Rob Harris, President & CEO of Tribute Pharmaceuticals points out that, "According to IMS, the prescription drug market in Canada for treating migraine headaches is valued at approximately one hundred and fifty million dollars."  Many Canadians who suffer from migraines are dissatisfied with their current medication and hope for a better treatment.  "Tribute Pharmaceuticals is very excited about the potential for CAMBIA™ in Canada and we look forward to building a strong partnership with Nautilus Neurosciences."

According to a survey published in the Journal of the American Board of Family Medicine, many people still hope to find a better treatment for their migraines, with more than a quarter dissatisfied w
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
2. US WorldMeds Acquires Solstice Neurosciences
3. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
4. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
5. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
6. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
7. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
8. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MONICA, Calif. , Aug. 28, 2014  In anticipation ... new infographic is being made available for the first time. ... San Diego offers a snapshot of ... industry. Highlighting everything from the latest employment statistics ... has made San Diego such a ...
(Date:8/28/2014)... Levi & Korsinsky announces that a class ... District Court for the District of Nevada ... Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... Period the Company violated federal securities laws by issuing ...
(Date:8/28/2014)... N.C. , Aug. 28, 2014   ... marketplace, today announced a worldwide search for product ... the senior population.  Promising ideas uncovered through the ... to leading medical device manufacturers and healthcare retailers ... improve the lives of individuals age 65 and ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen,(Paris:IPN) announced ... III study for its investigational 4-month formulation,of triptorelin ... triptorelin for a duration of 4 months in ... the second,administration as planned in the protocol. No ...
... 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today presented preliminary ... an adenosine A1 receptor antagonist in development for ... (CHF),that indicate a strong trend toward efficacy for ... a higher rate of,improvement in dyspnea, or shortness ...
Cached Medicine Technology:Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4
(Date:8/29/2014)... (PRWEB) August 29, 2014 The Florida ... the Hyatt Regency Orlando last week August 21-24 and ... returned as a presenter. , Dr. Greenstein ... the 21st Century was a standing room session; (2) ... – Doctors of Chiropractic Leading the Way in Injury ...
(Date:8/29/2014)... August 29, 2014 Canadian Healthy ... Canada, recently completed its annual survey of its 200 ... emerged of the products that appeal to Canadian consumer ... asked to list their top five selling healthy snacks ... is an increasingly important issue for consumers, employers, and ...
(Date:8/29/2014)... 2014 The Department of Health ... (FDA), Center for Food Safety and Applied Nutrition ... quantity (IDIQ) contract and the first two task ... Modernization and Enhancement (DME) for FARM VI” to ... Overarching contract objectives include:, ,     Upgrade ...
(Date:8/29/2014)... 2014 Under Section 946.300, Qualifications for ... “The physician shall not…advertise in a cultivation center or ... What the state of Illinois has done is create ... potential patients entering their care. The goal is to ... pharmacies and with typical prescription medications. Medical steering is ...
(Date:8/28/2014)... August 29, 2014 Career Step, an ... released a new video designed to help students and ... coding and billing field. The video details what medical ... for these professionals, and the education requirements for entering ... option that’s often overlooked when people are considering a ...
Breaking Medicine News(10 mins):Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 3Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 2Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 3Health News:Medical Marijuana Company Provides Solution for Illinois Marketing Regulations 2Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2
... ... Consumer Confidence That Will Come With These Long Awaited Manufacturing Regulations, , ... (PRWEB) June ... heralds the Food and Drug Administration,s (FDA) final step in enforcing its current ...
... ... targets an audience of teens and young adults in an effort to empower parents to ... , ... -- Kids Into Safe Skin (K.I.S.S) announced today the official launch of its not-for-profit organization, ...
... men can recall familiar faces faster and more accurately ... both sides of their brains, according to a new ... in the journal, Laterality: Asymmetries of Body, Brain ... orientation and whether we,re right-or-left-handed on our ability to ...
... UK,s National Physical Laboratory (NPL) is involved in a collaborative ... viral protein structure which could lead to new molecular medicines. ... from NPL, the University of Edinburgh and IBM T.J. Watson ... of Physical Chemistry B . The article sets out ...
... More ... ... EBSCO Publishing (EBSCO) began providing key database content free of charge in 2008 ... routines. Two free EBSCOhost® resources, GreenFILE™ , and Library, Information Science & ...
... cesareans due to ,failed inductions, researchers find , TUESDAY, ... doubles the risk of having a cesarean delivery, according ... to a link that experts have long suspected. , ... study author Dr. Deborah Ehrenthal, director of women,s health ...
Cached Medicine News:Health News:Small Supplement And Vitamin Manufacturers Must Meet FDA cGMP Requirements By The End Of The Month 2Health News:Small Supplement And Vitamin Manufacturers Must Meet FDA cGMP Requirements By The End Of The Month 3Health News:Small Supplement And Vitamin Manufacturers Must Meet FDA cGMP Requirements By The End Of The Month 4Health News:Kids Into Safe Skin (K.I.S.S) Officially Launches Today with a Mission to Create Awareness About Skin Cancer Detection and Prevention 2Health News:Kids Into Safe Skin (K.I.S.S) Officially Launches Today with a Mission to Create Awareness About Skin Cancer Detection and Prevention 3Health News:Kids Into Safe Skin (K.I.S.S) Officially Launches Today with a Mission to Create Awareness About Skin Cancer Detection and Prevention 4Health News:Gay men's bilateral brains better at remembering faces: York U study 2Health News:Viral protein structure study offers HIV therapy hope 2Health News:Free Resources from EBSCO Publishing Providing Useful Information to Researchers 2Health News:Free Resources from EBSCO Publishing Providing Useful Information to Researchers 3Health News:Free Resources from EBSCO Publishing Providing Useful Information to Researchers 4Health News:Labor Induction May Boost C-Section Risk 2Health News:Labor Induction May Boost C-Section Risk 3
... Vitrasert implant is a device ... with Aids-related Cytomegalovirus (CMV) Retinitis. This ... CMV when compared with conventional intravenous ... embedded in a polymer-based system that ...
Includes near contrast sensitivity card, calibrated holder, light meter, answer key and instruction manual contrast vision test developed by Arthur P. Ginsburg, Ph.D....
Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
Near PT test card/shorthand /PH stock market 5 1/2 " X 8"...
Medicine Products: